

ASIAN JOURNAL OF PHARMACEUTICAL
AND BIOLOGICAL RESEARCH

AJPBR



Indexed by:



Universal
Impact Factor



IMPACT FACTOR
SEARCH

Editorial board

Dr. Madhu Bala Scientist 'F' and Joint Director, Institute of Nuclear Medicine and Allied Sciences (INMAS), India

Dr. Sandip Narayan Chakraborty

Research Asst, Translational Molecular Pathology, Ut Md Anderson Cancer Center, Life Sciences Plaza, Houston, TX 77030

Dr. Tushar Treembak Shelke

Head of Department of Pharmacology and Research Scholar, In Jspms Charak College of Pharmacy & Research, Pune, India

Dr. Subas Chandra Dinda

Professor-cum-Director: School of Pharmaceutical Education & Research (SPER), Berhampur University, Berhampur, Orissa, India.

Dr. Jagdale Swati Changdeo

Professor and Head, Department of Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, S.No.124,MIT Campus,Kothrud, Pune-411038

Dr. Biplab Kumar Dey

Principal, Department of Pharmacy, Assam downtown University, Sankar Madhab Path, Panikhaiti 781026, Guwahati, Assam, India

Dr. Yogesh Pandurang Talekar

Research Associate, National Toxicology Centre

Dr. Indranil Chanda

Assistant Professor, Girijananda Chowdhury Institute of Pharmaceutical Science, Hathkhowapara, Azara Guwahati-17, Assam, India.

Dr. Sudip Kumar Mandal Department of Pharmaceutical Chemistry, Dr. B. C. Roy College of Pharmacy & AHS, Bidhannagar, Durgapur-713206, India.

Sodikova Dilrabokhon Andijan state medical institute

Dr., associate professor Kuryazova Sharofat Tashkent Pediatric medical institute

Dr., Abdurakhmanova Nigora Nazimovna Tashkent Pediatric Medical Institute

Abdullaeva Umida Bukhara state medical institute

Dr. Neeraj Upmanyu

Prof., Peoples Institute of Pharmacy & Research Center, Bhopal, MP, India.

Dr. Mirrakhimova Maktuba Khabibullaevna Tashkent medical academy Uzbekistan

Dr. Nishanova Aziza Abdurashidovna, Tashkent State Dental Institute

Dr. Sadikova Minurakhon Adkhamovna Andijan State Medical Institute

Kurbanova Sanobar Yuldashevna Tashkent State Dental Institute

Zokirova Nargiza Bahodirovna Tashkent Pediatric medical institute

Khabilov Behzod Nigmon ugli Tashkent State Dental Institute

Dr. Domenico De Berardis Department of Mental Health, Azienda Sanitaria Locale Teramo, 64100 Teramo, Italy

Dr. Azizova Rano Baxodirovna associate professor of the Department of neurology of the Tashkent Medical Academy

Dr. Ishankhodjaeva Gulchekhra Tashkent Medical Academy

Institute of Nuclear Medicine and Allied Sciences (INMAS), India

Brig SK Mazumdar Marg, Timarpur, New Delhi, Delhi 110054 India

PROSPECTS FOR OF INHIBITORS OF TUMOR NECROSIS FACTOR- α IN THE TREATMENT OF ANKYLOSING SPONDILOARTHRITIS

**Pulatova Shakhnoza Bakhtiyarovna, Abduazizova Nargiza Khakimzhanovna
Tashkent Medical Academy, Tashkent, Uzbekistan**

Abstract: A review of recommendations for the use of tumor necrosis factor α (TNF- α) inhibitors in patients with ankylosing spondylitis (AS) is presented. The data on the efficacy of TNF- α in patients with AS are presented. On the basis of international and domestic recommendations, indications for the appointment of this therapy, criteria for assessing its effectiveness and safety are formulated.

Keywords: ankylosing spondylitis; tumor necrosis factor- α inhibitors; efficiency; safety.

Introduction. Ankylosing spondylitis (AS) is a chronic inflammatory disease from the group of spondyloarthritis (SpA), characterized by a mandatory lesion of the sacroiliac joints (SIJ) and / or the spine with a potential outcome in ankylosis, with frequent involvement in the pathological process of entheses and peripheral joints. The progression of the disease is primarily associated with the proliferation of bone tissue, manifested mainly by the growth of syndesmophytes (and / or enthesophytes) and the process of ankylosis, usually the SIJ [1]. The first report on the clinical efficacy of TNF- α in SpA was published in 2000. These data were obtained in a pilot study of a small group of patients receiving infliximab (IFN) [4]. The possibilities of AS therapy have now expanded significantly. A new class of drugs that has appeared over the past decade and a half - tumor necrosis factor α (TNF- α) inhibitors - provide rapid clinical improvement and a positive effect on the quality of life in SpA [2]. In addition, there is evidence that long-term use of them slows down the progression of the disease [3]. Later, the results were confirmed in prospective controlled studies [5]. In 2001, data appeared on the effectiveness of etanercept (ETC) [2], in 2004 - adalimumab (ADA), in 2008 - golimumab (GLM) [12] and in 2013 - certolizumab pegol (CP) [3].

Based on the studies carried out in 2003, the first recommendations for the use of TNF- α in AS were created [6]. Later, under the auspices of the International Expert Group for the Study of SpondyloArthritis (ASAS, Assessment of SpondyloArthritis International Society), they were systematically updated. In 2011, expanded recommendations on the use of TNF- α in patients with axial SpA (axSpA) [7] appeared, and in the summer of 2013, recommendations were published on the treatment of SpA to achieve the goal [8]. According to international and domestic recommendations, IFNO- α should be prescribed to a patient with a diagnosis of AS, established on the basis of the modified New York criteria, or to patients with axSpA, who meet the ASAS 2009 criteria [9]. In this case, a high activity of the disease should be present: BASDAI ≥ 4.0 (Bath Ankylosing Spondylitis Disease Activity Index) or ASDAS > 2.1 (Ankylosing Spondylitis Disease Activity Score), which persists despite standard therapy - at least two consecutively prescribed non-steroidal anti-inflammatory drugs (NSAIDs), used in a full dose for a total of at least 4 weeks in the axial variant of the disease, and in the peripheral (presence of arthritis) - NSAIDs in combination with sulfasalazine and local administration of glucocorticoids (GC). The positive opinion of the expert is separately taken into account [10]. For an objective assessment of disease activity, the ASDAS index is increasingly used as an integral indicator, which includes not only clinical, but also laboratory parameters [5].

It should be noted that, according to the opinion of Russian experts, it is possible to prescribe IFNO- α for AS not only with high disease activity, but also for patients without signs of activity from the musculoskeletal system if they have such unfavorable prognosis factors as recurrent anterior uveitis that does not respond to standard therapy, or progressive coxitis. It has been proven that in the early stages of SpA, the effectiveness of TNF- α is significantly higher [11]. At the same time, predictors of a good response to drugs in this group are: young age, short duration of the disease, low level of functional impairment, high level of C-reactive

protein (CRP) and / or ESR, HLA-B27-positivity and the presence of signs of active inflammation according to MRI data. [one]. At the same time, according to previous studies, it is the condition of patients with active inflammation (osteitis) according to MRI who are positive for HLA-B27 and have high CRP levels that are more likely to progress to the radiologically significant stage of sacroiliitis [7], i.e. e. to the AC. There is an opinion that such patients with typical clinical symptoms of SpA who do not have reliable X-ray signs of sacroiliitis, but with changes in the SIJ characteristic of SpA on MRI in the T2-FatSat / STIR mode can be regarded as patients with early AS [3]. According to another point of view, they are classified as patients with non-radiological axSpA (nr-axSpA) [11]. In the case of initiation of TNF- α therapy in patients with ax-SpA, including those with nr-axSpA, the drugs of choice according to the registered indications are CZP, ETC and GLM.

It should be emphasized that when clinical remission is achieved during treatment with TNF- α , it is not recommended to completely cancel NSAIDs, since their effect on the progression of AS is manifested only with continuous administration and does not depend on the activity of the disease [12]. It has been shown that TNF- α has virtually no effect on X-ray progression (new bone formation) of the disease during the first 2–4 years of therapy. However, the results of later studies demonstrate that with their long-term use (over 4 years), the formation of syndesmophytes slows down significantly. Thus, the inhibition of the progression of the disease is observed only after prolonged and continuous use of TNF- α [8].

When a clinical effect is achieved (low activity or clinical remission), it is not recommended to immediately reduce the dose, increase the interval between drug injections or cancel it. The patient should receive the same dose of TNF- α for at least 3 months according to the standard administration regimen, and only then, depending on the clinical situation, it may be possible to gradually increase the intervals. A successful experience of increasing the intervals of administration of

ETC, INF, ADA without loss of effectiveness in most patients has been described [5]. At the same time, the probability of maintaining the achieved result is higher in the presence of a short duration of the disease, high activity before the start of therapy with a rapid decrease in it in the first 3 months, and the absence of extra-skeletal manifestations [6].

A number of studies suggest that the appointment of TNF- α in the early stages, when chronic foci of inflammation have not yet formed, probably prevents the development of structural changes and the growth of syndesmophytes. Currently, there are data on the maintenance of drug-free remission in patients with early SpA after a long course of this therapy [5,13,14].

There are some differences in the effectiveness between different TNF- α in terms of the effect on the extraskeletal manifestations of AS, which must be taken into account when choosing them. In inflammatory bowel diseases, it is necessary to use only monoclonal antibodies (INF, ADA, GLM, CZP), and in uveitis, their effectiveness is slightly higher than that of soluble receptors (ETC). However, if it is impossible to use monoclonal antibodies to TNF α in AS patients with uveitis, ETC can be an adequate substitute [13,17,18, 20, 21]. At the same time, with a high risk of activation of tuberculosis infection, the appointment of soluble receptors is more expedient [22-35].

Before and during treatment with TNF- α , patients should undergo regular examinations, during which the development of active tuberculosis should be excluded and the dynamics of the state of latent tuberculosis infection should be assessed. For this, screening for tuberculosis (chest X-ray, tuberculin diagnostics (Mantoux test with 2 TE), and / or a test for the release of interferon γ in vitro (QuantiFERON © -TBGold), and / or / or a skin test with a recombinant tuberculosis allergen (Diaskintest®). Patients should be monitored by a phthisiatrician for another 6 months after the completion of TNF- α therapy.

TNF- α therapy in carriers of hepatitis C virus (HCV) and especially hepatitis B virus (HBV) should be carried out with extreme caution and under close laboratory supervision. The risk of reactivation of the infection can be reduced if the viral load and the level of hepatic enzymes are monitored before the appointment of therapy and throughout its duration (at least once every 3 months). If necessary, treatment with TNF- α is carried out after preliminary antiviral therapy, which is prescribed by a hepatologist or infectious disease specialist, or against the background of such treatment.

Treatment of TNF- α in patients with congestive heart failure can lead to its decompensation, therefore the use of TNF- α in such patients should be carried out with extreme caution and in accordance with the following principles: patients with compensated heart failure (NYHA class I and II) need conduct an echocardiographic study; patients with normal ejection fraction ($> 50\%$) can receive therapy with close monitoring of clinical manifestations; in patients with advanced heart failure, therapy should be interrupted; it is impossible to prescribe TNF- α to patients with decompensated heart failure.

Treatment with TNF- α is considered effective if, 12 weeks after its initiation, BASDAI decreases by 50% or at least 2 points, ASDAS decreases by more than 1.1. If during this period the patient does not achieve 20% improvement on the BASDAI, he should be transferred to another TNF- α . In this case, the effectiveness of the second TNF- α will be higher if the first is canceled due to loss of effectiveness, and not due to primary inefficiency [13,14].

Conclusion. One of the reasons for the ineffectiveness of TNF- α may be the immunogenicity of these drugs. Chimeric drugs are more likely to induce an immune response than fully human TNF- α . By itself, the presence of antibodies to the drug does not correlate with a decrease in the effectiveness of treatment. Thus, the frequency of detecting antibodies to INF ranges from 12 to 44%, to ADA - from 1 to 87%, to ETC - from 0 to 18%, with no apparent effect on their effectiveness

or the incidence of adverse reactions. At the same time, it has been demonstrated that a high level of antibodies to INF and ADA is associated with their lower efficiency [11-19]. Currently, there are works in which the use of methotrexate and, to a lesser extent, sulfasalazine for SpA allowed to reduce the level of antibodies and immunogenicity of drugs [10,16,18], to increase the duration of effective therapy. In general, with the development of secondary ineffectiveness of TNF- α , it is preferable to transfer the patient to a drug from this group, but with a different mechanism of action.

References

1. Erdes SH.F. Basic principles of therapy for ankylosing spondylitis (ankylosing spondylitis). Scientific and practical rheumatology. 2013; 51 (6): 686-95
3. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012; 71 Suppl 2: i2-45. doi: 10.1136 / annrheumdis-2011-201036.
2. Ganiyeva N.A., Rizamukhamedova M.Z., Nabiyeva D.A., Aripova N.A. Clinic - diagnostic aspects of modern biomarkers of early atherosclerosis and fibrotic activity of systemic scleroderma // Asian Journal of Medical Principles and Clinical Practice. – 2021. - № 4(3). – P. 1-13.
3. Khidoyatova M. R. et al. Diagnosis of heart dysfunction in patients with COVID-19 //Asian journal of pharmaceutical and biological research. – 2022. – T. 11. – №. 3.
4. Mukhammadieva S.M., Nabieva D.A., Abduazizova N.X., Xidoyatova M.R. Clinical efficacy and tolerability of infliximab in patients with severe ankylosing spondylitis. Original Medicine. Volume 1 Issue 1 2022. ISSN 2729-8043 Impact Factor Search 5 <https://www.original-medicine.eu/P.8-16>.
5. Nabiyeva D.A. Dyslipidaemia and Cytokine Profile in patients with Gout: the role of IL-6, IL-18 and hyperuricemia in the development of metabolic disorders // Journal of Advances in Medicine and Medical research.- 2017.- № (23.12.).- 1-10.

6. Nabiyeva D.A. Dyslipidaemia and Cytokine Profile in patients with Gout: the role of IL-6, IL-18 and hyperuricemia in the development of metabolic disorders // Journal of Advances in Medicine and Medical research. - 2017.- № (23.12.) 1-10.
7. Nabiyeva D. A. Quality of life of gouty patients //European journal of researchs. – 2017. – T. 5. – №. 5.
8. Nasonov E.L., editor. Rheumatology: Clinical guidelines. 2nd ed. Moscow: GEOTAR-Media; 2010.752 c.
9. Sagatova D.R Modern Aspects Of The Pathogenetic Mechanisms Of The Osteoarthritis. // World journal of advanced scientific research Modern Aspects. 29-47 pp. World J Adv Sci Res Vol. 4 Issue 4 July - August 2021.
10. Aripov A.N., Nabieva D.A. Biomarkers and algorithm of laboratory diagnostics of rheumatic diseases // "Metabolic syndrome: pathogenesis, diagnosis and treatment" abstracts of the Republican scientific and practical conference.- 2011.- p.184. [in Russian]
11. Aripova N.A., Juraeva E.R. Tizimli scleroderma interleukin-4 clinics aʻamiyati// Tibbietda yangi kun, Bukhoro, - 2022. – №12(50). – Pp. 18-24. [in Russian]
12. Ganieva N.A., Rizamukhamedova M.Z. Diagnostic aspects of modern biomarkers of early atherosclerosis in patients with systemic scleroderma// Bulletin of the Tashkent Medical Academy. -2022. – No. 2. – pp.157-159. [in Russian]
13. Mukhammadieva S.M., Nabieva D.A. The study of the effectiveness of adalimumab in the treatment of axial spondyloarthritis. All-Russian Congress with international participation "Days of Rheumatology in St. Petersburg – 2022". October 20-21, 2022, pp.101-102. [in Russian]
14. Mukhammadieva S.M., Nabieva D.A., Ziyaeva F.K., Mirkhamidov M.V., Shiranova Sh.A. Evaluation of the effectiveness of yema necrosis factor inhibitors in the treatment of ankylosing spondyloarthritis. "Journal of biomedicine and Practice"8 Vols, 1son (No. 1 2023y.) Pp. 294-302. [in Uzbek]

15. Nabieva A.H., Bekenova G.T., Alimova N.Z., Khasanova Sh.A. Adherence to therapy among patients with a therapeutic profile. Bulletin of the Magistracy. 2023. No. 2-1 (137), pp. 16-20. [in Russian]
16. Nabieva D.A. Laboratory diagnostics of acute phase response in arthritis // "Metabolic syndrome: pathogenesis, diagnosis and treatment" theses of the Republican scientific and practical conference. 2011.- p.184. [in Russian]
17. Nabieva D.A., Mukhamedova N.H. Parallelism of multiple injuries in non-alcoholic fatty liver disease in patients with gout and pseudopodagra // Uzbekiston tibbiyot jurnali-2017.- No. 6.- pp. 83-87. [in Russian]
18. Nabieva D.A., Mukhammadieva S.M. The effectiveness of TNF- α inhibitors in the treatment of uveitis in patients with ankylosing spondylitis. Innovative technologies in Healthcare: New Opportunities for Internal Medicine 22-April, 2022, p. 142. [in Russian]
19. Nabieva D.A., Tashpulatova M.M. Predictors of development of metabolic disorders in patients with tophaceous gout and asymptomatic hyperuricemia // Bulletin of the Association of Physicians, scientific and practical medical journal of Uzbekistan.- 2017.- No. 4.- pp. 76-83. [in Russian]
20. Pulatova Sh.B., Nabieva D.A., Alieva K.K. The value of the proinflammatory cytokine interleukin-17 in ankylosing spondylitis. All-Russian Therapeutic Congress with international participation "Botkin Readings" St. Petersburg – 2021, From 233. [in Russian]
21. Sagatova Dr., Nabieva D.A., Rajapov M., Muminova N.I. The role of endothelial dysfunction in the development of osteoarthritis in women in the menopausal period // Vestnik TMA. No. 2, 2022, 121-125 p. [in Russian]
22. Abdullaeva U.K., Sobirova G.N., Karimov M.M., Aslonova I.J. The prevalence and possibilities of prevention of noncardial gastric cancer in the Bukhara region // American journal of medicine and medical sciences. 2020. Vol. 10. Iss. 9. P. 679-681.

23. Abdullaeva U.K. Predicting the risk of atrophic transformation in chronic gastritis using serum pepsinogen // World journal of pharmaceutical research, Faculty of Pharmacy Medical University, Bulgaria. 2019. Vol. 8. Iss. 13. P. 219-228.
24. Abdullaeva U.K., Shadjanova N.S. Using the OLGA system in chronic atrophic gastritis // New day in medicine. 2020. Iss. 13. P. 9-12.
25. Abdullayeva U.K. The value of interactive teaching methods in improving the level of clinical knowledge of students // Medical education and professional development. 2019. Vol. 1. Iss. 33. P. 29-33. (in Russian)
26. Abdullaeva U.K. Predicting the risk of atrophic transfusion in gastritis with chronic helicobacter // Tashkent. Abstract of PhD dissertation. 2021. P.1-46. (in Uzbek)
27. Abdullaeva U.K. Opportunities to prevent atrophic changes in the gastric mucosa in the Bukhara region // Journal bulletin of the doctor. 2020. Vol. 1, Iss.31. P. 7-11. (in Uzbek)
28. Abdullaeva U.K. Retrospective analysis of gastritis associated with chronic atrophic H. pylori in patients with nocardial gastric cancer in bukhara city and prevention of atrophic processes of gastric mucosa // Interdisciplinary Approaches to Medicine. 2022. Vol. 3, Iss.2. P. 10-13.
29. Abdullayeva U.K., Shadmanov M.A. A new approach to the treatment of ulcerative colitis // Art of Medicine. International Medical Scientific Journal. 2022. Vol. 2, Iss.1.
30. Abdullayeva U.K., Shadmanov M.A. New aspects of the diagnosis of ulcerative colitis // British Medical Journal. 2022. Vol. 2, Iss.1.
31. Abdullayeva U.K., Rakhimova M.B. Clinical-anamnestic features of patients with H. pylori-associated chronic gastritis in the Bukhara Region // Biology. 2022. Iss. 5. P. 139. (in Uzbek)

32. U.K. Abdullaeva Regional causes of extrahepatic subtransaminasemias // Journal of Problems of Biology and Medicine. 2018. Vol. 3. Iss. 102. P. 8-10. (in Russian)
33. Abdullayeva U.K., Zhalolova V.Z. To study the effectiveness of cholelolytic therapy in patients with gallstone disease, taking into account the type of violation of the contractility of the gallbladder // Bulletin of the Council of Young Scientists and Specialists of the Chelyabinsk region. 2016. Iss. 4 (15). P. 4-6. (in Russian)
34. Abdullayeva U.K. Results of morphological and endoscopic examination in chronic gastritis // Journal of theoretical and clinical medicine. 2022. № 3. P. 46-49. (in Uzbek)
35. Abdullayeva U.K., Mirzayeva D.B. Regional perspectives of metabolic therapy of stable angina pectoris // Kazakhstan Republican scientific journal “Vestnik” 2019. Vol. 1. Iss. 85. P. 74-75. (in Russian)